Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | IMGN151 |
Synonyms | |
Therapy Description |
IMGN151 is an antibody-drug conjugate (ADC) comprising an anti-FOLR1 (FRalpha) antibody linked to a maytansinoid-derivative, which potentially leads to killing of tumor cells expressing FOLR1 and reduced tumor growth (Cancer Res (2020) 80 (16_Supplement): 2890). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
IMGN151 | IMGN-151|IMGN 151 | FOLR1-targeted Therapy 24 | IMGN151 is an antibody-drug conjugate (ADC) comprising an anti-FOLR1 (FRalpha) antibody linked to a maytansinoid-derivative, which potentially leads to killing of tumor cells expressing FOLR1 and reduced tumor growth (Cancer Res (2020) 80 (16_Supplement): 2890). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05527184 | Phase I | IMGN151 | First in Human Study of IMGN151 in Recurrent Endometrial Cancer and Recurrent, High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers | Recruiting | USA | 0 |